Shariati, A and Nemati, R and Sadeghipour, Y and Yaghoubi, Y and Baghbani, R and Javidi, K and Zamani, M and Hassanzadeh, A (2020) Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier. European Journal of Cell Biology, 99 (6). ISSN 01719335
Full text not available from this repository.Abstract
Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) along with some other less common diseases generally described by the advanced deterioration of central or peripheral nervous system, structurally or functionally. In the last two decades, mesenchymal stromal cells (MSCs) due to their unique assets encompassing self-renewal, multipotency and accessibility in association with low ethical concern open new frontiers in the context of neurodegenerative diseases therapy. Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages (e.g., neurons, oligodendrocyte, and astrocyte), and thus could be employed to advance cell-based therapeutic strategy. Additionally, as inflammation ordinarily ensues as a local response provoked by microglia in the neurodegenerative diseases, MSCs therapy because of their pronounced immunomodulatory properties is noticed as a rational approach for their treatment. Recently, varied types of studies have been mostly carried out in vitro and rodent models using MSCs upon their procurement from various sources and expansion. The promising results of the studies in rodent models have motivated researchers to design and perform several clinical trials, with a speedily rising number. In the current review, we aim to deliver a brief overview of MSCs sources, expansion strategies, and their immunosuppressive characteristics and discuss credible functional mechanisms exerted by MSCs to treat neurodegenerative disorders, covering AD, PD, ALS, MS, and HD.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Cell therapyExpansionImmunomodulatory propertiesMesenchymal stromal cells (MSCs)Neurodegenerative diseasesSource |
| Subjects: | R Medicine > RZ Other systems of medicine |
| Divisions: | Other Resources |
| Depositing User: | خدیجه شبانکاره |
| Date Deposited: | 22 Dec 2020 10:26 |
| Last Modified: | 22 Dec 2020 10:26 |
| URI: | http://eprints.bpums.ac.ir/id/eprint/9046 |
Actions (login required)
 |
View Item |
